Abstract P234 Table 1.

Lung function, dyspnoea and health status improvements in QVA149 vs placebo — subgroup analyses based on prior medicationuse and disease severity.

	1	LSM (SE) treatment difference of QVA149 vs placebo
FEV₁AUC_5min-4h(L)	Trough FEV₁(L)	TDI total score	SGRQ total score

Prior medication use
β-agonist plus steroid	0.34 (0.030)^***	0.19 (0.030)^***	1.21 (0.406)^**	–4.09 (1.705)^*
LABA	0.36 (0.059)^***	0.25 (0.058)^***	0.71 (0.798)^ns	–0.34 (3.103)^ns
LAMA	0.33 (0.028)^***	0.22 (0.029)^***	1.48 (0.443)^***	–5.94 (1.770)^***
SABA	0.37 (0.032)^***	0.22 (0.031)^***	1.29 (0.430)^**	–3.10 (1.780)^ns
SAMA	0.30 (0.074)^***	0.18 (0.073)^*	2.27 (1.135)^*	–3.24 (4.495)^ns
β-agonist plus anticholinergic	0.31 (0.075)^***	0.08 (0.079)^ns	1.13 (1.222)^ns	–4.66 (4.935)^ns
None	0.30 (0.033)^***	0.17 (0.034)^***	0.97 (0.500)^ns	–2.30 (2.198)^ns
COPD severity
Moderate	0.37 (0.021)^***	0.24 (0.021)^***	1.17 (0.294)^***	–2.74 (1.257)^*
Severe	0.26 (0.031)^***	0.12 (0.031)^***	1.00 (0.433)^*	–3.77 (1.840)^*

↵***P<0.001 **;P<0.01; *P<0.05; ns, non-significant
LSM, least squares mean; SABA,short-acting β₂-agonist; SAMA, short-acting muscarinic antagonist; SE, standard error